ADAP — Adaptimmune Therapeutics Share Price
0.000.00%
Last trade - 00:00- $20.54m
- -$13.61m
- $178.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.96% | ||
| Return on Equity | n/a | ||
| Operating Margin | -36.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.96 | 6.15 | 27.15 | 60.28 | 178.03 | 43.15 | 64.67 | 175.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Directors
- David Mott NEC (55)
- Adrian Rawcliffe CEO (49)
- Gavin Wood CFO (51)
- William Bertrand COO (56)
- Elliot Norry SVP (58)
- John Lunger OTH (52)
- Cintia Piccina OTH (49)
- Helen Tayton-Martin OTH (54)
- James Noble NED (62)
- Lawrence Alleva NID (71)
- Ali Behbahani NID (44)
- Barbara Duncan NID (56)
- John Furey NID (56)
- Elliott Sigal NID (69)
- Tal Zvi Zaks NID (56)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 3rd, 2014
- Public Since
- May 6th, 2015
- No. of Shareholders
- 27
- No. of Employees
- 506
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,590,309,546
- Address
- 60 Jubilee Avenue, Milton Park, ABINGDON, OX14 4RX
- Web
- https://www.adaptimmune.com/
- Phone
- +44 1235430000
- Auditors
- KPMG LLP
Upcoming Events for ADAP
Q3 2025 Adaptimmune Therapeutics PLC Earnings Release
Similar to ADAP
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the Adaptimmune Therapeutics share price?
As of Today at 19:04 UTC, shares in Adaptimmune Therapeutics are trading at $0.08. This share price information is delayed by 15 minutes.
How has the Adaptimmune Therapeutics share price performed this year?
Shares in Adaptimmune Therapeutics last closed at $0.08 and the price had moved by -92.15% over the past 365 days. In terms of relative price strength the Adaptimmune Therapeutics share price has underperformed the S&P500 Index by -93.43% over the past year.
What are the analyst and broker recommendations for Adaptimmune Therapeutics?
The overall consensus recommendation for Adaptimmune Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Adaptimmune Therapeutics dividend yield?
Adaptimmune Therapeutics does not currently pay a dividend.
Does Adaptimmune Therapeutics pay a dividend?
Adaptimmune Therapeutics does not currently pay a dividend.
When does Adaptimmune Therapeutics next pay dividends?
Adaptimmune Therapeutics does not currently pay a dividend.
How do I buy Adaptimmune Therapeutics shares?
To buy shares in Adaptimmune Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adaptimmune Therapeutics?
As of the previous close price of $0.08, shares in Adaptimmune Therapeutics had a market capitalisation of $20.54m.
Where are Adaptimmune Therapeutics shares listed?
Here are the trading details for Adaptimmune Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADAP
What kind of share is Adaptimmune Therapeutics?
Based on an overall assessment of its quality, value and momentum Adaptimmune Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adaptimmune Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Adaptimmune Therapeutics is $1.16. That is 1396.77% above the last closing price of $0.08.
Analysts covering Adaptimmune Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
Find out moreWhat is the trend in the Adaptimmune Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptimmune Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -88.13%.
As of the last closing price of $0.08, shares in Adaptimmune Therapeutics were trading -82.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adaptimmune Therapeutics PE Ratio?
The Adaptimmune Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adaptimmune Therapeutics?
Adaptimmune Therapeutics' management team is headed by:
- David Mott - NEC
- Adrian Rawcliffe - CEO
- Gavin Wood - CFO
- William Bertrand - COO
- Elliot Norry - SVP
- John Lunger - OTH
- Cintia Piccina - OTH
- Helen Tayton-Martin - OTH
- James Noble - NED
- Lawrence Alleva - NID
- Ali Behbahani - NID
- Barbara Duncan - NID
- John Furey - NID
- Elliott Sigal - NID
- Tal Zvi Zaks - NID